Aquestive Therapeutics, Inc.

Good morning, and welcome to the Equestria Therapeutics second quarter conference call. At this time, all participants are in a list-only mode. Later, there will be a question-and-answer session, and instructions will be given at that time. If anyone requires any assistance on today's call, please press star and zero on your touch-tone telephone. As a reminder, this call will be recorded. I would now like to introduce your host for today's conference, Ms. Lauren Walrath, Head Corporate Marketing and Communications.

You may begin. Thank you, Operator.

Good morning, and welcome to today's call to review Equestive Therapeutics results for the second quarter 2019 and business highlights, as well as the top line data from the Liberman Crossover Study. On today's call, I am joined by Keith Kendall, Chief Executive Officer, and John Maxwell, Chief Financial Officer, who are going to provide an overview of recent business developments and performance in Q2 of this year. Additional members of our leadership team will be available for the Q&A at the end of the call. In total, we expect today's call to last approximately 60 minutes. As a reminder, our remarks today correspond with the earnings release we issued after market closed yesterday. In addition, a recording of today's call will be made available on Equestria Therapeutics' website within the Investor Relations section shortly following the conclusion of the call. To remind you, we will be discussing some non-GAAP financial measures this morning as part of our review of second quarter 2019 results. A description of these measures, along with the reconciliation to GAAP, can be found in the earnings release we issued yesterday. During the call, the company will be making forward-looking statements. We remind you of the company's safe harbor language as outlined in yesterday's earnings release, as well as the risks and uncertainties affecting the company as described in the risk factors section included in the company's annual report on Form 10-K filed with the SEC on March 14, 2019 and in our quarterly reports on Form 10-Q. As with any pharmaceutical company with product candidates under development, there are significant risks and uncertainties with respect to our business and the development regulatory approval and commercialization of our products. and other matters related to operations. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. Actual results may differ materially from these statements. All subsequent forward-looking statements attributable to Equestria Therapeutics or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement and the cautionary statements contained in the earnings release issued yesterday. The company assumes no obligation to update its forward-looking statements after the date of this conference call, whether as a result of new information, future events, or otherwise, except as required under applicable law. With that, I will now turn the line over to Keith.